Company intelligence / Profile preview

Aexon Labs

Lewes, Delaware, United States

Ownership: Private
Development stage: Other

Overview

The company has published a recent patent (WO2024115797) for dual non-sulfonamide orexin receptor agonists demonstrating stable pharmacological profiles, improved safety (non-sulfonamide classification to reduce side effects), and early promising in vitro data for narcolepsy and neurodegenerative disease. The compounds address both symptomatology and underlying neuronal destruction (e.g., cathepsin inhibition), but none are yet in clinical trials.

Therapeutic areas: Neurology
Modalities: Small moleculeChemical drug
Industry: Biotech

Drug pipeline

7 assets

AEX-3

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

NLS Pharmaceutics (Swiss public biopharma; global licensing and development agreement for dual orexin agonist platform)

Beyond the preview

Go deeper on Aexon Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aexon Labs.

Explore the full profile